Oncology Breast Cancer - FOI Response Register

FoI Number
2024-691
Subject
Oncology Breast Cancer
Date Received
07/02/2025
Request and Response
  1. How many patients have been treated for breast cancer (any stage) in the past 3 months with the following systemic anti-cancer therapies:

Abemaciclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole)

 

Abemaciclib + Fulvestrant

 

Alpelisib + Fulvestrant

 

Anthracycline (e.g. doxorubicin or epirubicin) + Cyclophosphamide

 

Aromatase Inhibitor as a single agent

 

Atezolizumab

 

Capecitabine as a single agent

 

Carboplatin + Paclitaxel

 

Elacestrant

 

Eribulin as a single agent or in combination

 

Everolimus + Exemestane

 

Fulvestrant as a single agent

 

Palbociclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole)

 

Palbociclib + Fulvestrant

 

Parp Inhibitors (Olaparib/Talazoparib)

 

Pembrolizumab

 

Pertuzumab (Perteja) + Trastuzumab (Herceptin)

 

Phesgo (Pertuzumab + Trastuzumab in a single injection)

 

Ribociclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole)

 

Ribociclib + Fulvestrant

 

Sacituzumab Govitecan

 

Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent 

 

Trastuzumab deruxtecan (Enhertu)

 

Trastuzumab (Herceptin) as a single agent or in combination with Paclitaxel

 

Trastuzumab emtansine (Kadcyla)

 

Any other active systemic anti-cancer therapy

 
  1. How many patients have been treated for metastatic breast cancer in the past 3 months with the following systemic anti-cancer therapies:

Phesgo (Pertuzumab + Trastuzumab in a single injection)

 

Pertuzumab (Perteja) + Trastuzumab (Herceptin)

 

Trastuzumab (Herceptin) as a single agent or in combination with Paclitaxel

 

Trastuzumab deruxtecan (Enhertu)

 

Trastuzumab emtansine (Kadcyla)

 

Given the small numbers of patients involved; the specific and sensitive nature of the health conditions referred to; the size of Shetland’s population; the specific treatments; and the short timeframe, NHS Shetland considers that providing any answers to questions 1 and 2 carries a high risk of identifying individuals. As such and in accordance with FOISA s 16(1), NHS Shetland confirms that it holds the information requested but that it is exempt from disclosure under FOISA s 38(1)(b) as read with s 38 (2A) as the information constitutes personal data and disclosure would breach the confidentiality of the data subjects.

  1. If breast cancer is not treated at or within the Trust, where are patients referred?

N/A